BioAdvance

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

KayoThera is a biotechnology company based in Princeton, New Jersey, focused on developing therapeutics for late-stage and metastatic cancers. Founded in 2019, the company aims to create first-in-class immuno- and targeted therapies that target a key enzyme responsible for protecting cancer cells, as well as depleting regulatory T-cells. This innovative approach seeks to enhance the effectiveness of existing treatments, such as chemotherapy and immunotherapy, thereby offering new hope to patients with previously incurable cancers. KayoThera's mission is centered on driving breakthroughs in cancer treatment and improving patient outcomes.

Phrase Health, Inc., founded in 2018 and based in Philadelphia, Pennsylvania, offers software solutions tailored for the healthcare sector. The company's platform is designed to help hospitals monitor and analyze the information provided to doctors and nurses at the point of care. By facilitating workflow management, Phrase Health enables healthcare professionals to identify actionable insights and supports data-driven process improvements. The software aids in decision-making and enhances user interaction, allowing for better coordination of strategic initiatives within healthcare environments.

Wellsheet, Inc. is a technology company that specializes in optimizing clinical workflows through its application, which integrates with existing electronic health records (EHR). Founded in 2015 and based in Newark, New Jersey, with an additional office in New York, the company utilizes artificial intelligence and machine learning to organize and present pertinent patient information in a streamlined format. By enabling healthcare providers to access relevant data quickly and effectively, Wellsheet enhances early intervention and improves overall hospital efficiency. The platform collaborates with major EHR vendors, including Epic and Cerner, to ensure seamless integration and distribution through a software-as-a-service model. Wellsheet's approach has demonstrated significant impact in large health systems, improving the accuracy and efficiency of patient care at the point of service.

Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Ride Health LLC is a New York-based company that provides a software-as-a-service (SaaS) platform designed to help healthcare providers manage patient transportation to medical appointments. Founded in 2016, Ride Health partners with healthcare organizations and transportation providers to streamline the scheduling, requesting, and payment processes for rides. The platform allows care coordinators to arrange rides in advance or on-demand and offers real-time insights into transportation costs and usage. By integrating technology and data with a personalized approach, Ride Health addresses transportation challenges faced by healthcare providers and payers, ensuring that patients receive rides tailored to their individual needs. Additionally, the company has implemented a COVID-19 ride tracking program to support hospitals across the nation, further enhancing patient access and improving healthcare outcomes.

Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia that specializes in developing gene therapies for cardiovascular diseases. Founded in 2013, Renovacor is focused on addressing dilated cardiomyopathy (DCM), a condition that affects over 3 million individuals in the United States. The company's lead program utilizes a recombinant adeno-associated virus (AAV) to create a gene therapy targeting patients with DCM caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This specific genetic mutation is estimated to affect around 35,000 individuals in the U.S. and a similar number in Europe, representing an orphan disease as defined by FDA guidelines. Patients with BAG3 mutations tend to be younger and experience a faster progression to advanced heart failure compared to those with ischemic heart disease. Currently, these patients receive standard heart failure treatments, but the five-year survival rate remains at only 50%. Renovacor aims to develop a BAG3 gene replacement therapy that could prevent disease progression in this vulnerable population.

Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.

Phrase Health, Inc., founded in 2018 and based in Philadelphia, Pennsylvania, offers software solutions tailored for the healthcare sector. The company's platform is designed to help hospitals monitor and analyze the information provided to doctors and nurses at the point of care. By facilitating workflow management, Phrase Health enables healthcare professionals to identify actionable insights and supports data-driven process improvements. The software aids in decision-making and enhances user interaction, allowing for better coordination of strategic initiatives within healthcare environments.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

ENB Therapeutics, LLC develops small molecule inhibitors to treat melanoma and other cancers. The product includes ENB-001 that restores the ability of T-cells to infiltrate tumors and inhibits metastasis. The company was incorporated in 2015 and is based in New York, New York.

Bainbridge Health, Inc. is a Philadelphia-based company that develops a clinical intelligence and data analytics platform focused on improving medication safety in hospital systems. Founded in 2016, the company provides solutions specifically for medication safety leaders, including an infusion pump management software known as InfusionWare. This platform allows clinicians to manage infusion data centrally, enhancing patient safety by streamlining data handling and reducing the likelihood of medication errors. Bainbridge Health’s vendor-agnostic approach eliminates the need for cumbersome data management practices, enabling hospitals to mitigate risks associated with medication errors while also lowering avoidable costs.

A biotech company, engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company was founded in 2012 and is headquartered in Bryn Mawr, Pennsylvania .

Oncora Medical, Inc. is a digital health company that specializes in developing an analytics platform aimed at enhancing the capabilities of radiation oncologists in delivering care to cancer patients. Founded in 2014 and based in Philadelphia, Pennsylvania, Oncora offers tools that facilitate the extraction and integration of clinical data from various sources, including electronic medical records and treatment planning software. This platform enables physicians to leverage historical data and predictive analytics for personalized treatment recommendations. Additionally, Oncora's software incorporates machine learning algorithms to analyze patient data, providing insights into treatment outcomes and improving decision-making in radiation oncology.

Wellsheet, Inc. is a technology company that specializes in optimizing clinical workflows through its application, which integrates with existing electronic health records (EHR). Founded in 2015 and based in Newark, New Jersey, with an additional office in New York, the company utilizes artificial intelligence and machine learning to organize and present pertinent patient information in a streamlined format. By enabling healthcare providers to access relevant data quickly and effectively, Wellsheet enhances early intervention and improves overall hospital efficiency. The platform collaborates with major EHR vendors, including Epic and Cerner, to ensure seamless integration and distribution through a software-as-a-service model. Wellsheet's approach has demonstrated significant impact in large health systems, improving the accuracy and efficiency of patient care at the point of service.

Genome Profiling, LLC is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers to aid in the diagnosis, treatment, and prediction of chronic and life-threatening diseases. Established in 2012 and located in Wayne, Pennsylvania, the company offers GenPro Analytics, a software platform designed for scientists and medical professionals. This platform improves the sensitivity, specificity, and accuracy of disease prediction and monitoring while also being cost-effective. Genome Profiling is notable for its innovative approach, combining a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms. This integration allows a single NGS run to generate comprehensive data for both genomic variant analysis and epigenetic research, positioning the company at the forefront of the emerging epigenetic biomarker market.

WellTrackONE, LLC is a population health management company based in Hilton Head Island, South Carolina, with an additional office in New York, New York. Founded in 2010, it specializes in providing wellness programs to healthcare providers, including rural health clinics and integrated delivery networks. The company focuses on administering Medicare Annual Wellness Visits, offering clinical risk management services that generate comprehensive baseline reports detailing modifiable risk factors, preventative goals, and measurable data. WellTrackONE supports healthcare professionals by scheduling, screening, and documenting wellness visits, while also providing critical data for accountable care organizations and helping payers maintain compliance with clinical indicators and quality measures. Through its customized wellness solutions, WellTrackONE aims to enhance patient care and improve health outcomes for Medicare patients across the United States.

CytoVas LLC develops informatics platform that provides information on novel cellular markers of disease progression and individual treatment response to clinicians and drug developers. The company's platforms include CLOUD CYTOMICS and CytoVas Vascular Health Profile. CLOUD CYTOMICS provides automated data collection, mining, and modeling solutions to clinical researchers. CytoVas Vascular Health Profile provides cytometric vascular health event detection test for clinical studies. The company was incorporated in 2010 and is headquartered in Philadelphia, Pennsylvania.

Olive Devices LLC is a company based in Philadelphia, Pennsylvania, that develops innovative smart glasses aimed at enhancing communication for individuals who are deaf or hard of hearing, as well as those with attention deficit disorder, early onset Alzheimer’s, and other communication or memory challenges. The smart glasses feature real-time speech-to-text captions that display in front of the user's eyes, facilitating better understanding in various settings. Additionally, Olive Devices offers a mobile application that complements the smart glasses by syncing captions to the cloud, allowing users to organize and utilize the information for note-taking and studying. The application also includes features for converting notes into memory games, tracking progress from educators, and enabling interactions between students and teachers. Founded in 2015, Olive Devices serves a diverse clientele, including teachers, students, parents, audiologists, and optometrists.

Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.

TalexMedical, LLC is a Philadelphia-based company that develops and manufactures a medical device designed to treat external ear deformities in newborns. Its primary product, Infantear, is a Class I medical device that offers a nonsurgical ear molding system. This system is applied in an outpatient setting, providing a cost-effective alternative to traditional surgical procedures. Infantear is customizable and made from soft materials, ensuring comfort for the patient. The treatment involves a straightforward two-week application during the first three weeks of life, which allows pediatricians to address ear anomalies without the need for referrals to specialists. Founded in 2015, TalexMedical aims to enhance healthcare outcomes by improving results, increasing patient satisfaction, and reducing costs.

Group K Diagnostics, Inc. is a Philadelphia-based company that develops and manufactures innovative point-of-care diagnostic devices focused on liver function testing. Its flagship product, MultiDiagnostic, is a multi-test modular diagnostic tool that utilizes paper-based microfluidics, enabling three diagnostic tests with just one drop of blood. The company also provides complementary mobile and desktop software that allows patients to capture and upload images of their sample cards to receive results efficiently. Founded in 2016, Group K Diagnostics aims to enhance patient care while reducing the burden on healthcare providers, offering a low-cost solution that integrates seamlessly into existing medical workflows and is designed to be reimbursable.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company based in Malvern, Pennsylvania, established in 2010. The company specializes in the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections, including challenging conditions caused by pathogens such as MRSA, Pseudomonas, and Salmonella. Venatorx has developed a robust in-house research and development organization that has filed over 100 patents across various research initiatives. The company has received substantial funding from notable organizations, including the National Institute of Allergy and Infectious Diseases, Wellcome Trust, and the Biomedical Advanced Research and Development Authority, as well as private equity investments from firms like Versant Ventures and Abingworth. This support highlights Venatorx's commitment to addressing critical public health challenges related to resistant infections.

Ride Health LLC is a New York-based company that provides a software-as-a-service (SaaS) platform designed to help healthcare providers manage patient transportation to medical appointments. Founded in 2016, Ride Health partners with healthcare organizations and transportation providers to streamline the scheduling, requesting, and payment processes for rides. The platform allows care coordinators to arrange rides in advance or on-demand and offers real-time insights into transportation costs and usage. By integrating technology and data with a personalized approach, Ride Health addresses transportation challenges faced by healthcare providers and payers, ensuring that patients receive rides tailored to their individual needs. Additionally, the company has implemented a COVID-19 ride tracking program to support hospitals across the nation, further enhancing patient access and improving healthcare outcomes.

Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.

Keriton LLC specializes in a pumped breast milk management system tailored for neonatal intensive care units (NICUs). Founded in 2016 and based in Philadelphia, Pennsylvania, the company addresses the challenges of breast milk management, which is often manual and error-prone. Its platform allows for real-time tracking of milk inventory, feeding orders, and provides notifications for expiry dates and misfeeds. Additionally, it enables nurses to share media with mothers and offers insights into lactating mothers' milk production patterns. By automating and validating the breast milk management process, Keriton significantly reduces the time nurses spend on these tasks, lowers the risk of errors, and creates an audit trail for compliance. The system aims to enhance the pumping experience for mothers, which is linked to better clinical outcomes for infants. Keriton's approach aligns with the goals of improving patient outcomes, reducing costs, and fostering better family engagement, presenting a potential return on investment for hospitals.

Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Cohero Health, Inc. is a digital respiratory health company that focuses on improving the management of asthma and chronic obstructive pulmonary disease (COPD). Founded in 2012 and based in New York, the company offers a proprietary connected health platform that combines sensor-based technology with a mobile application. This platform includes the BreatheSmart app, which provides customized medication reminders, records inhaler usage, and tracks lung function, symptoms, and environmental conditions over time. Cohero Health's product suite features mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker that monitors both control and rescue medications. Additionally, BreatheSmart Connect serves as a Software-as-a-Service solution for remote patient monitoring and communication, enhancing coordination between patients and healthcare providers. By utilizing these tools, Cohero Health aims to improve medication adherence and overall health outcomes for individuals with respiratory conditions.

Genome Profiling, LLC is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers to aid in the diagnosis, treatment, and prediction of chronic and life-threatening diseases. Established in 2012 and located in Wayne, Pennsylvania, the company offers GenPro Analytics, a software platform designed for scientists and medical professionals. This platform improves the sensitivity, specificity, and accuracy of disease prediction and monitoring while also being cost-effective. Genome Profiling is notable for its innovative approach, combining a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms. This integration allows a single NGS run to generate comprehensive data for both genomic variant analysis and epigenetic research, positioning the company at the forefront of the emerging epigenetic biomarker market.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Bainbridge Health, Inc. is a Philadelphia-based company that develops a clinical intelligence and data analytics platform focused on improving medication safety in hospital systems. Founded in 2016, the company provides solutions specifically for medication safety leaders, including an infusion pump management software known as InfusionWare. This platform allows clinicians to manage infusion data centrally, enhancing patient safety by streamlining data handling and reducing the likelihood of medication errors. Bainbridge Health’s vendor-agnostic approach eliminates the need for cumbersome data management practices, enabling hospitals to mitigate risks associated with medication errors while also lowering avoidable costs.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

Olive Devices LLC is a company based in Philadelphia, Pennsylvania, that develops innovative smart glasses aimed at enhancing communication for individuals who are deaf or hard of hearing, as well as those with attention deficit disorder, early onset Alzheimer’s, and other communication or memory challenges. The smart glasses feature real-time speech-to-text captions that display in front of the user's eyes, facilitating better understanding in various settings. Additionally, Olive Devices offers a mobile application that complements the smart glasses by syncing captions to the cloud, allowing users to organize and utilize the information for note-taking and studying. The application also includes features for converting notes into memory games, tracking progress from educators, and enabling interactions between students and teachers. Founded in 2015, Olive Devices serves a diverse clientele, including teachers, students, parents, audiologists, and optometrists.

Penn State Health Milton S. Hershey Medical Center is a 551-bed Level I regional trauma center. As Central Pennsylvania’s only academic medical center and home to the Children’s Hospital at Penn State Health Milton S. Hershey Medical Center and Penn State College of Medicine, we are looked to as a resource for the most complex adult and pediatric cases. We have earned ANCC Magnet Recognition, which confirms our commitment to provide a professional environment that supports staff development and quality patient care.

Cohero Health, Inc. is a digital respiratory health company that focuses on improving the management of asthma and chronic obstructive pulmonary disease (COPD). Founded in 2012 and based in New York, the company offers a proprietary connected health platform that combines sensor-based technology with a mobile application. This platform includes the BreatheSmart app, which provides customized medication reminders, records inhaler usage, and tracks lung function, symptoms, and environmental conditions over time. Cohero Health's product suite features mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker that monitors both control and rescue medications. Additionally, BreatheSmart Connect serves as a Software-as-a-Service solution for remote patient monitoring and communication, enhancing coordination between patients and healthcare providers. By utilizing these tools, Cohero Health aims to improve medication adherence and overall health outcomes for individuals with respiratory conditions.

Noble.MD is a healthcare technology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company has developed Theo, a digital healthcare advisory platform designed to assist patients in identifying health and behavioral risks. It engages patients in managing these risks through targeted programs and interventions. The platform captures essential patient data at the point of care, facilitating value-based reimbursement and streamlining the alignment of provider and payer interests. By focusing on real-time patient engagement and data collection, Noble.MD aims to enhance risk identification, coding, and management in modern healthcare settings.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Oncora Medical, Inc. is a digital health company that specializes in developing an analytics platform aimed at enhancing the capabilities of radiation oncologists in delivering care to cancer patients. Founded in 2014 and based in Philadelphia, Pennsylvania, Oncora offers tools that facilitate the extraction and integration of clinical data from various sources, including electronic medical records and treatment planning software. This platform enables physicians to leverage historical data and predictive analytics for personalized treatment recommendations. Additionally, Oncora's software incorporates machine learning algorithms to analyze patient data, providing insights into treatment outcomes and improving decision-making in radiation oncology.

Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

RiboNova Inc. is a biomedical research company based in Wynnewood, Pennsylvania, incorporated in 2011. The company focuses on developing small molecule drugs aimed at a novel class of targets: defective transfer RNAs. RiboNova's mission includes creating precision medicines to address serious rare diseases, particularly genetically confirmed mitochondrial disease and certain types of cancer. By targeting ribonucleic acid anomalies, RiboNova aims to provide innovative therapies that enable healthcare professionals to better treat patients affected by these challenging conditions.

Cohero Health, Inc. is a digital respiratory health company that focuses on improving the management of asthma and chronic obstructive pulmonary disease (COPD). Founded in 2012 and based in New York, the company offers a proprietary connected health platform that combines sensor-based technology with a mobile application. This platform includes the BreatheSmart app, which provides customized medication reminders, records inhaler usage, and tracks lung function, symptoms, and environmental conditions over time. Cohero Health's product suite features mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker that monitors both control and rescue medications. Additionally, BreatheSmart Connect serves as a Software-as-a-Service solution for remote patient monitoring and communication, enhancing coordination between patients and healthcare providers. By utilizing these tools, Cohero Health aims to improve medication adherence and overall health outcomes for individuals with respiratory conditions.

Hsiri Therapeutics is a development stage pharmaceutical company engaged in the discovery and development of new antibiotics to treat diseases caused by drug resistant bacteria. Hsiri Therapeutics’ efforts are primarily directed at two discrete groups of pathogens – mycobacterial diseases and gram-negative infections. Hsiri Therapetics was formed based on the antibiotic research that originated in the laboratories of Professor Marvin Miller at the University of Notre Dame.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

CarePartners Plus, LLC is a technology-enabled healthcare communication and data company based in Horsham, Pennsylvania. Founded in 2009, it specializes in providing patient management solutions that enhance healthcare experiences through its cloud-based platform, Wellby. This system offers patient engagement tools designed to improve care connections and facilitate a cultural shift towards personalized healthcare. CarePartners Plus focuses on capturing and analyzing patient-generated data to support compliance and better health outcomes. Its services cater to a diverse range of stakeholders, including pharmaceutical companies, health insurers, hospitals, employers, government agencies, and patients. The company's evidence-based engagement programs promote both provider-requested and self-initiated data gathering, contributing to improved care coordination and cost containment in the healthcare system.

Allevi develops tools for designing and engineering 3D tissues, specializing in desktop 3D bioprinters that create functional living tissues. The company's offerings include bioinks composed of collagen and hyaluronic acid, alongside a cloud-based platform called Bioprint Online, which allows users to design structures, define materials, and monitor the printing process. Allevi's products are utilized by researchers in tissue engineering, regenerative medicine, material science, and cell biology, as well as by industrial and pharmaceutical companies for drug testing and development. The company's bioinks are available for purchase online. Founded in 2014 and based in Philadelphia, Pennsylvania, Allevi was previously known as BioBots, Inc.

WellTrackONE, LLC is a population health management company based in Hilton Head Island, South Carolina, with an additional office in New York, New York. Founded in 2010, it specializes in providing wellness programs to healthcare providers, including rural health clinics and integrated delivery networks. The company focuses on administering Medicare Annual Wellness Visits, offering clinical risk management services that generate comprehensive baseline reports detailing modifiable risk factors, preventative goals, and measurable data. WellTrackONE supports healthcare professionals by scheduling, screening, and documenting wellness visits, while also providing critical data for accountable care organizations and helping payers maintain compliance with clinical indicators and quality measures. Through its customized wellness solutions, WellTrackONE aims to enhance patient care and improve health outcomes for Medicare patients across the United States.

Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

HealthQX, founded in 2012 and based in King of Prussia, Pennsylvania, specializes in value-based payment analytic software solutions tailored for health plans and providers. The company's primary offering, ClarityQx, is a comprehensive analytics platform designed to facilitate the design, implementation, and ongoing performance monitoring of various payment models, including episodic, bundled, and accountable care arrangements. This platform provides users with drill-down dashboards that enhance provider engagement and streamline contract negotiation processes. By enabling quick access to critical payment analytics, HealthQX aims to improve consumer care and reduce medical costs within the healthcare industry.

TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses​ to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Hsiri Therapeutics is a development stage pharmaceutical company engaged in the discovery and development of new antibiotics to treat diseases caused by drug resistant bacteria. Hsiri Therapeutics’ efforts are primarily directed at two discrete groups of pathogens – mycobacterial diseases and gram-negative infections. Hsiri Therapetics was formed based on the antibiotic research that originated in the laboratories of Professor Marvin Miller at the University of Notre Dame.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Ossianix Inc. is a biotherapeutics company that specializes in developing single domain antibodies derived from the VNAR structure of sharks. Founded in 2012 and headquartered in Philadelphia, Pennsylvania, with research facilities in Stevenage, United Kingdom, Ossianix utilizes its VNAR platform to create high-affinity products that address various therapeutic targets. This innovative approach allows for the rapid development of bispecific and trispecific antibodies, which can be tailored for specific clinical applications, including targeting the blood-brain barrier and gastrointestinal tract. The company has also established a strategic research collaboration with Lundbeck A/S to advance its drug discovery programs across different therapeutic areas.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York that focuses on developing innovative treatments for central nervous system (CNS) diseases and chronic pain management. The company's lead product candidate, d-Methadone, is currently undergoing Phase II clinical trials for conditions such as depression and neuropathic pain. In addition to d-Methadone, Relmada is also working on LevoCap ER, an abuse-resistant formulation of levorphanol; BuTab, an oral version of buprenorphine; and MepiGel, a topical formulation of mepivacaine designated for orphan drug status. Founded in 2004, Relmada aims to address significant unmet medical needs within the pain management and CNS therapeutic areas through its diversified portfolio of drug candidates.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York that focuses on developing innovative treatments for central nervous system (CNS) diseases and chronic pain management. The company's lead product candidate, d-Methadone, is currently undergoing Phase II clinical trials for conditions such as depression and neuropathic pain. In addition to d-Methadone, Relmada is also working on LevoCap ER, an abuse-resistant formulation of levorphanol; BuTab, an oral version of buprenorphine; and MepiGel, a topical formulation of mepivacaine designated for orphan drug status. Founded in 2004, Relmada aims to address significant unmet medical needs within the pain management and CNS therapeutic areas through its diversified portfolio of drug candidates.

BioDetego is developing, VASPfore, a new biomarker test for selecting cancer treatment protocols. The VASP marker provides information that will direct chemotherapy to high risk patients who will likely benefit from treatment while preventing costly and harmful treatment of low risk patients. BioDetego predicts that the VASPfore will provide payors enormous savings (>$150MM/year) by reducing total treatment costs. The company is led by David Zuzga, Ph.D., Founder and CEO, a research scientist with expertise in cell and molecular biology at La Salle University & Giovanni M. Pitari, M.D., Ph.D. Founder and CSO, a physician and research scientist with expertise in Translational Oncology.

HealthQX, founded in 2012 and based in King of Prussia, Pennsylvania, specializes in value-based payment analytic software solutions tailored for health plans and providers. The company's primary offering, ClarityQx, is a comprehensive analytics platform designed to facilitate the design, implementation, and ongoing performance monitoring of various payment models, including episodic, bundled, and accountable care arrangements. This platform provides users with drill-down dashboards that enhance provider engagement and streamline contract negotiation processes. By enabling quick access to critical payment analytics, HealthQX aims to improve consumer care and reduce medical costs within the healthcare industry.

InfraScan, Inc. is a medical device company that specializes in developing and distributing hand-held diagnostic devices for assessing head injuries and strokes using near-infrared (NIR) technology. Its primary product, the Infrascanner, allows healthcare professionals to detect intracranial bleeding in patients with head trauma, which is crucial for timely intervention. The device is applicable in various settings, including hospitals, military operations, remote screenings, sports medicine, pediatrics, and ambulance services. InfraScan was founded in 2004 and is headquartered in Philadelphia, Pennsylvania, where it also operates a research and development lab. The company markets its products through a network of distributors across North America, South America, Africa, Asia, the Middle East, and Europe.

Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company based in Malvern, Pennsylvania, established in 2010. The company specializes in the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections, including challenging conditions caused by pathogens such as MRSA, Pseudomonas, and Salmonella. Venatorx has developed a robust in-house research and development organization that has filed over 100 patents across various research initiatives. The company has received substantial funding from notable organizations, including the National Institute of Allergy and Infectious Diseases, Wellcome Trust, and the Biomedical Advanced Research and Development Authority, as well as private equity investments from firms like Versant Ventures and Abingworth. This support highlights Venatorx's commitment to addressing critical public health challenges related to resistant infections.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Microbiota is spun out from university of Pennsylvania, to develop a gut microbiome-based treatment for hyperammonemia.

Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.

Ossianix Inc. is a biotherapeutics company that specializes in developing single domain antibodies derived from the VNAR structure of sharks. Founded in 2012 and headquartered in Philadelphia, Pennsylvania, with research facilities in Stevenage, United Kingdom, Ossianix utilizes its VNAR platform to create high-affinity products that address various therapeutic targets. This innovative approach allows for the rapid development of bispecific and trispecific antibodies, which can be tailored for specific clinical applications, including targeting the blood-brain barrier and gastrointestinal tract. The company has also established a strategic research collaboration with Lundbeck A/S to advance its drug discovery programs across different therapeutic areas.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Life Mist Technologies, Inc., based in Paoli, Pennsylvania, specializes in developing atomization technology that utilizes low-pressure gas and liquid to create a high volume of micron-sized droplets. This innovative technology is applied across various industrial sectors, including aircraft fire suppression, chemical processing, emission control, turbine inlet cooling, artificial snow production, and decontamination. The company aims to enhance existing processes and provide effective solutions for pathogen control, particularly in healthcare settings. Established in 2004, Life Mist Technologies continues to focus on diverse applications of its atomization technology to meet the needs of its clients.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Innovative Supply Solutions LLC, a specialty contract service organization, provides clinical drug supply chain management services. Its services include planning/forecasting for API/formulated product needs, project management, budget projection/management, packaging design, inventory management, supply chain coordination and management, IVR/IWR supply design and management, manufacturing coordination, packaging and labeling coordination, distribution coordination, analytical services coordination, product sourcing, material destruction coordination, and consultancy. The company is based in Southampton, Pennsylvania.

Anakim Biologics is developing efficiencies and improvements in biologics manufacturing;

Treventis Corporation is an early-stage biotechnology company specializing in the treatment of diseases linked to protein misfolding, including Alzheimer's, Parkinson's, and Huntington's diseases. The company is focused on developing small molecule drugs that can penetrate the brain and neutralize misfolded proteins, with the goal of halting the progression of Alzheimer's disease and other dementias. Treventis is also working on companion diagnostics that facilitate the early detection of Alzheimer's, enabling timely intervention to minimize neuronal loss. Their innovative approach aims to block amyloid toxicity while minimizing side effects for patients.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York that focuses on developing innovative treatments for central nervous system (CNS) diseases and chronic pain management. The company's lead product candidate, d-Methadone, is currently undergoing Phase II clinical trials for conditions such as depression and neuropathic pain. In addition to d-Methadone, Relmada is also working on LevoCap ER, an abuse-resistant formulation of levorphanol; BuTab, an oral version of buprenorphine; and MepiGel, a topical formulation of mepivacaine designated for orphan drug status. Founded in 2004, Relmada aims to address significant unmet medical needs within the pain management and CNS therapeutic areas through its diversified portfolio of drug candidates.

Innovative Supply Solutions LLC, a specialty contract service organization, provides clinical drug supply chain management services. Its services include planning/forecasting for API/formulated product needs, project management, budget projection/management, packaging design, inventory management, supply chain coordination and management, IVR/IWR supply design and management, manufacturing coordination, packaging and labeling coordination, distribution coordination, analytical services coordination, product sourcing, material destruction coordination, and consultancy. The company is based in Southampton, Pennsylvania.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Melior Discovery, Inc. is a biopharmaceutical company that focuses on identifying new therapeutic applications for existing drugs through its innovative in vivo pharmacology platform. Established in 2005 and based in Exton, Pennsylvania, Melior employs its theraTRACE indications discovery platform to systematically evaluate single compounds across multiple in vivo models. This approach allows for the rapid and cost-effective identification of potential uses in various therapeutic areas, including neurodegenerative diseases, inflammation, pain management, metabolic disorders, gastrointestinal and urological conditions, cardiovascular diseases, and dermatology. Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, providing valuable insights for pre-clinical and development-stage candidates.

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Imiplex LLC is a biotechnology company based in Bristol, Pennsylvania, that specializes in developing protein-based nanotechnology for various applications, including targeted therapeutics, biosensors, and functional biomaterials. Founded in 2003, the company offers a platform called TriPol, which consists of modular components designed from proteins. This platform enables the construction of diverse nanostructures by leveraging the unique properties of proteins, such as their capability for self-assembly with atomic precision and their structural diversity. Imiplex utilizes recombinant DNA technology for engineering these proteins, ensuring scalable production and versatility in its applications.

COOL~BIO is a biotechnology company focused on developing hypothermia-activated biologics. Therapeutic hypothermia (TH) is the process of cooling the body to prevent organ damage and is widely-used in cardiac surgery, ischemic stroke, cardiac arrest, neurosurgery and traumatic brain injury. Their lead molecule is an anti-platelet agent being developed for use during cardiopulmonary bypass.

CarePartners Plus, LLC is a technology-enabled healthcare communication and data company based in Horsham, Pennsylvania. Founded in 2009, it specializes in providing patient management solutions that enhance healthcare experiences through its cloud-based platform, Wellby. This system offers patient engagement tools designed to improve care connections and facilitate a cultural shift towards personalized healthcare. CarePartners Plus focuses on capturing and analyzing patient-generated data to support compliance and better health outcomes. Its services cater to a diverse range of stakeholders, including pharmaceutical companies, health insurers, hospitals, employers, government agencies, and patients. The company's evidence-based engagement programs promote both provider-requested and self-initiated data gathering, contributing to improved care coordination and cost containment in the healthcare system.

Solaris Therapeutics

Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.

RMH Sciences aims to commercialize newly discovered antibiotics by Dr. Harvey Rubin, University of Pennsylvania Professor of Medicine. One of RMH’s most promising ventures focuses on creating antibiotics to combat hospital acquired bacterial pathogens, a largely unmet need in the current marketplace.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Solaris Therapeutics

Melior Discovery, Inc. is a biopharmaceutical company that focuses on identifying new therapeutic applications for existing drugs through its innovative in vivo pharmacology platform. Established in 2005 and based in Exton, Pennsylvania, Melior employs its theraTRACE indications discovery platform to systematically evaluate single compounds across multiple in vivo models. This approach allows for the rapid and cost-effective identification of potential uses in various therapeutic areas, including neurodegenerative diseases, inflammation, pain management, metabolic disorders, gastrointestinal and urological conditions, cardiovascular diseases, and dermatology. Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, providing valuable insights for pre-clinical and development-stage candidates.